United Therapeutics Corporation
Shareholders Approve United Therapeutics 2026 Stock Incentive Plan
Summary
On June 26, 2026, United Therapeutics Corporation's shareholders approved the 2026 Stock Incentive Plan, which replaces the prior 2015 plan and allows for the issuance of up to 6,454,385 shares. The plan aims to incentivize non-employee directors, officers, employees, and service providers. Additionally, the meeting saw the election of directors and approval of executive compensation and the ratification of Ernst & Young LLP as the independent auditor.
Profitelligence Alerts
Get alerts for UTHR
Be first to know when United Therapeutics Corporation files with the SEC.
Filing Categories
Advertisement
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Official SEC Documents
Advertisement